Related Experiment Video

Updated: Aug 6, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Targeting the Bcl-2 family in cancer therapy

Kyriakos Papadopoulos1

  • 1Institute for Drug Development, Cancer Therapy and Research Center, and Division of Medical Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, TX, USA. kpapadop@idd.org

Seminars in Oncology
|August 8, 2006
PubMed

Insights

Targeting anti-apoptotic Bcl-2 proteins, like Bcl-2, aims to trigger tumor cell death by modulating apoptosis. This review covers Bcl-2 family roles and new drug inhibitors, including antisense oligonucleotides and small molecules.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • The Bcl-2 protein family regulates apoptosis, a key process in cancer development.
  • Dysregulation of apoptosis, particularly the overactivity of anti-apoptotic proteins like Bcl-2, promotes tumor survival.
  • Targeting these proteins offers a strategy to induce cancer cell death.

Purpose of the Study:

  • To review the current understanding of Bcl-2 family proteins in apoptosis.
  • To discuss strategies for targeting anti-apoptotic Bcl-2 proteins in cancer therapy.
  • To highlight recent developments in drug inhibitors for Bcl-2 family proteins.

Main Methods:

  • Literature review of scientific publications.
  • Analysis of research on Bcl-2 family function in apoptosis.
  • Examination of drug development strategies for Bcl-2 inhibition.

Main Results:

  • Bcl-2 family proteins play a critical role in the intrinsic apoptosis pathway.
  • Targeting anti-apoptotic members, especially Bcl-2, is a promising therapeutic strategy.
  • Antisense oligonucleotides and small molecule inhibitors are key drug classes under development.

Conclusions:

  • Modulating the intrinsic apoptosis pathway by targeting Bcl-2 proteins is a viable approach for cancer treatment.
  • Ongoing research and drug development are advancing the therapeutic potential of Bcl-2 inhibitors.
  • These targeted therapies hold promise for improving outcomes in various cancers.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.